Johnson & Johnson $JNJ Shares Sold by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. decreased its position in Johnson & Johnson (NYSE:JNJ) by 5.5% in the 2nd quarter, Holdings Channel.com reports. The fund owned 258,233 shares of the company’s stock after selling 15,023 shares during the period. Johnson & Johnson makes up 0.9% of Tocqueville Asset Management L.P.’s investment portfolio, making the stock its 28th largest position. Tocqueville Asset Management L.P.’s holdings in Johnson & Johnson were worth $65,583,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. Auto Owners Insurance Co boosted its holdings in Johnson & Johnson by 22,225.6% in the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after purchasing an additional 69,108,368 shares during the period. Norges Bank acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $6,924,523,000. Capital World Investors acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $2,005,942,000. Diamant Asset Management Inc. lifted its position in shares of Johnson & Johnson by 24,436.5% in the 1st quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock worth $109,338,000 after buying an additional 4,454,778 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Johnson & Johnson by 41.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,423,886 shares of the company’s stock valued at $2,571,124,000 after buying an additional 3,655,754 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $265.79 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. Johnson & Johnson has a 12-month low of $173.33 and a 12-month high of $276.47. The business has a 50 day simple moving average of $259.57 and a 200 day simple moving average of $244.17. The firm has a market capitalization of $640.53 billion, a price-to-earnings ratio of 30.80, a price-to-earnings-growth ratio of 2.56 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. The business had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business’s revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is 62.11%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson continues to attract attention as a defensive, income-oriented healthcare holding. Commentary highlights the company’s history of maintaining and increasing dividends through recessions, which may support demand from long-term and retirement-focused investors. Two Recessions Couldn’t Stop These 4 Healthcare Stocks From Raising Dividends
• Positive Sentiment: An article reviewing J&J’s investments in 15 biotech and medtech companies points to potential strategic value and future upside from its investment portfolio, although these holdings are not currently a major earnings driver. Johnson & Johnson Owns Stakes in 15 Stocks. Here’s the Best of the Bunch.
• Neutral Sentiment: J&J will hold a conference call on October 13 to discuss third-quarter results. Chief Executive Officer Joaquin Duato, Chief Financial Officer Joseph Wolk, and other executives will participate. The event could provide a catalyst through updated guidance, pharmaceutical sales trends, and management commentary, but it does not change current fundamentals. Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
• Neutral Sentiment: Recent commentary compares JNJ’s performance with the consumer-staples sector and highlights its exposure to artificial-intelligence-related investments. These themes may improve investor visibility, but neither represents a new company announcement or near-term earnings catalyst. Johnson & Johnson Stock: Is JNJ Outperforming the Consumer Staples Sector?

Insider Buying and Selling

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president directly owned 23,003 shares in the company, valued at $5,779,963.81. This trade represents a 50.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 63,972 shares of company stock worth $16,245,605 in the last 90 days. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on JNJ shares. Scotiabank reiterated an “outperform” rating and set a $305.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. The Goldman Sachs Group reiterated a “buy” rating and set a $282.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. Wells Fargo & Company raised their price target on Johnson & Johnson from $272.00 to $282.00 and gave the stock an “overweight” rating in a report on Monday, August 3rd. Morgan Stanley upped their price objective on Johnson & Johnson from $284.00 to $294.00 and gave the stock an “overweight” rating in a research note on Thursday, July 16th. Finally, HSBC set a $290.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $268.22.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.